New innovations: Therapeutic opportunities for intellectual disabilities
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Intellectual disability is common and is associated with significant morbidity. Until the latter half of the 20th century, there were no efficacious treatments. Following initial breakthroughs associated with newborn screening and metabolic corrections, little progress was made until recently. With improved understanding of genetic and cellular mechanisms, novel treatment options are beginning to appear for a number of specific conditions. Fragile X and tuberous sclerosis offer paradigms for the development of targeted therapeutics, but advances in understanding of other disorders such as Down syndrome and Rett syndrome, for example, are also resulting in promising treatment directions. In addition, better understanding of the underlying neurobiology is leading to novel developments in enzyme replacement for storage disorders and adjunctive therapies for metabolic disorders, as well as potentially more generalizable approaches that target dysfunctional cell regulation via RNA and chromatin. Physiologic therapies, including deep brain stimulation and transcranial magnetic stimulation, offer yet another direction to enhance cognitive functioning. Current options and evolving opportunities for the intellectually disabled are reviewed and exemplified. Ann Neurol 2013;74:382–390
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Identification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“It also regulates translation of these transcripts by inhibition of the mGluR5 glutamate receptor.(16) This receptor stimulates sp6 kinase translation for production of the proteins which create the dendritic outgrowths that interface with other neurons and allow signals to cross at the dendritic synaptic junction.”
Reversal of Neurological Defects in a Mouse Model of Rett Syndrome
Guy, J., Gan, J., Selfridge, J., Cobb, S., & Bird, A. (2007) · Science · doi:10.1126/science.1138389 · Cited by 1,230 · cited 1×
“Mouse models for Rett syndrome show abnormal paw movements remarkably analogous to the human defects, and in these mice replacement of MeCP2 restored at least partial function.(67,68) These mouse studies suggested that MeCP2 does not have essential functions in brain development and that interventions put in place aft…”
Regulation of histone acetylation during memory formation in the hippocampus
Levenson, J. M., O'Riordan, K. J., Brown, K. D., Trinh, M. A., Molfese, D. L., & Sweatt, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402229200 · Cited by 1,131 · cited 1×
“Histone acetylation appears to be involved in memory formation; its level increases in the brain following learning.(97,98) Many ID disorders associated with deficient memory formation, including Rubinstein–Taybi syndrome (RTS) and fragile X syndrome, show decreased histone acetylation.”
Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5401 · Cited by 1,046
Chromatin Acetylation, Memory, and LTP Are Impaired in CBP+/− Mice
Alarcón, J. M., Malleret, G., Touzani, K., Vronskaya, S., Ishii, S., Kandel, E. R., & Barco, A. (2004) · Neuron · doi:10.1016/j.neuron.2004.05.021 · Cited by 892
Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827 · cited 1×
“The protein mTOR, which regulates both mGluR5 and ERK—itself a regulator of pS6kinase translation and central to RNA translation—was identified as a potential target for treatment by a number of groups.(55,56) Several drugs targeting the mTOR pathway are in clinical trial or design, and show promise in both preclinica…”
CBP Histone Acetyltransferase Activity Is a Critical Component of Memory Consolidation
Korzus, E., Rosenfeld, M. G., & Mayford, M. (2004) · Neuron · doi:10.1016/j.neuron.2004.06.002 · Cited by 823 · cited 1×
“Histone acetylation appears to be involved in memory formation; its level increases in the brain following learning.(97,98) Many ID disorders associated with deficient memory formation, including Rubinstein–Taybi syndrome (RTS) and fragile X syndrome, show decreased histone acetylation.”
Cited by
Genetic studies in intellectual disability and related disorders
Vissers, L. E. L. M., Gilissen, C., & Veltman, J. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg3999 · Cited by 761
Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
Zamboni, V., Jones, R., Umbach, A., Ammoni, A., Passafaro, M., Hirsch, E., & Merlo, G. R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061821 · Cited by 83
Validation of the NIH Toolbox Cognitive Battery in intellectual disability
Shields, R. H., Kaat, A. J., McKenzie, F. J., Drayton, A., Sansone, S. M., Coleman, J., Michalak, C., Riley, K., Berry-Kravis, E., Gershon, R. C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009131 · Cited by 73
Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis
Curie, A., Yang, K., Kirsch, I., Gollub, R. L., des Portes, V., Kaptchuk, T. J., & Jensen, K. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133316 · Cited by 43
“Yet, novel and hopefully more efficient treatment options for ID are beginning to appear for a number of specific conditions, such as DS and FX [3].”
BackgroundSearching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Caraci, F., Iulita, M. F., Pentz, R., Flores Aguilar, L., Orciani, C., Barone, C., Romano, C., Drago, F., & Cuello, A. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.004 · Cited by 18
Metadata
- Authors
- Picker, J. D., & Walsh, C. A.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-09
- Volume
- 74
- Issue
- 3
- Pages
- 382-390
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2161494048
- Cited by
- 34
- References
- 28
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New innovations: Therapeutic opportunities for intellectual disabilities. https://app.cochat.ai/papers/10.1002/ana.24002
- The paper
- Picker, J. D., & Walsh, C. A. (2013). New innovations: Therapeutic opportunities for intellectual disabilities. Annals of Neurology. https://doi.org/10.1002/ana.24002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.